OKYO Pharma Ltd
okyopharma.comWhat Do They Do?
Develops topical drug candidates for corneal and anterior-segment diseases, including urcosimod for neuropathic corneal pain.
20-F for FY2026, filed Jul 20, 2026We are a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. The…View ↗
Our research program focuses on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of specific…View ↗
Urcosimod, our novel, non-opioid therapeutic candidate, is designed to target and alleviate the debilitating pain associated with corneal…View ↗
How Are They Changing?
Treatment focus
Earlier, the company described its lead drug candidate as being developed for dry eye disease, with neuropathic corneal pain among possible additional indications; the latest report says it switched further development to neuropathic corneal pain.
20-F for FY2023, filed Aug 15, 2023 20-F for FY2026, filed Jul 20, 2026We are a clinical-stage biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from…View ↗
In mid-2024, we made the final decision to switch all further clinical development of urcosimod to the treatment of Neuropathic Cornea Pain…View ↗
Loading...
